Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

pSivida to Present At Two Investment Conferences in September



  pSivida to Present At Two Investment Conferences in September

Rodman & Renshaw Global Investment Conference 2013 Stifel Nicolaus 2013 Global
Healthcare Conference

Business Wire

WATERTOWN, Mass. -- September 4, 2013

pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a
leader in developing sustained release drugs for treatment of back-of-the-eye
diseases, will present at two upcoming investor conferences in September.

pSivida will present at the Rodman & Renshaw Annual Global Investment
Conference being held at the Millennium Broadway Hotel in New York on Tuesday,
September 10 at 12:05 p.m. This presentation will be webcast and can be found
at the following link: http://wsw.com/webcast/rrshq23/PSDV. Follow the
official Rodman & Renshaw handle on Twitter @rodman_2013 and use #rodman2013
for conference information and updates.

pSivida will also present at the Stifel Nicolaus Healthcare Conference being
held at the Four Seasons Boston Hotel, in the Winthrop Room, on Thursday,
September 12 at 11:30 a.m. and will also be webcast:
http://www.veracast.com/webcasts/stifel/healthcare2013/98207674667.cfm. All
times are Eastern.

About pSivida

pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained
release, drug delivery products designed to deliver drugs at a controlled and
steady rate for months or years. pSivida is currently focused on treatment of
chronic diseases of the back of the eye utilizing its core technology systems,
Durasert™ and BioSilicon™. The injectable, sustained release micro-insert
ILUVIEN® for the treatment of chronic DME considered insufficiently responsive
to available therapies, licensed to Alimera Sciences, Inc., has received
marketing authorization in Austria, France, Germany, Portugal, Spain and the
U.K. and is awaiting authorization in Italy. Alimera has resubmitted the New
Drug Application for ILUVIEN for DME to the U.S. Food and Drug Administration.
pSivida plans to institute pivotal Phase III clinical trials for the treatment
of posterior uveitis, a chronic back-of-the-eye disease, with the same
micro-insert as ILUVIEN for DME. An investigator-sponsored clinical trial is
ongoing for an injectable, bioerodible micro-insert to treat glaucoma and
ocular hypertension. pSivida's FDA-approved Retisert® licensed to Bausch &
Lomb Incorporated provides long-term, sustained drug delivery to treat
posterior uveitis.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF
1995:

Various statements made in this release are forward-looking, and are
inherently subject to risks, uncertainties and potentially inaccurate
assumptions. All statements that address activities, events or developments
that we intend, expect or believe may occur in the future are forward-looking
statements. The following are some of the factors that could cause actual
results to differ materially from the anticipated results or other
expectations expressed, anticipated or implied in our forward-looking
statements: uncertainties with respect to: determination of the price and
reimbursement conditions for ILUVIEN in France; Alimera's ability to obtain
regulatory approval for, and if approved, to finance, successfully
commercialize and achieve market acceptance of, and generate revenues to
pSivida from, ILUVIEN for DME in the U.S.; Alimera's ability to finance,
achieve additional marketing approvals, achieve appropriate pricing and
reimbursement and successfully commercialize and achieve market acceptance of,
and generate revenues to pSivida from, ILUVIEN for DME in the EU; the success
of Phase III posterior uveitis trials including efficacy, side effects and
risk/benefit profile of the posterior uveitis micro-insert and pSivida’s
ability to finance and complete the trials and receive marketing approvals;
initiation, financing and success of Latanoprost Product Phase II trials and
exercise by Pfizer of its option; development of products using Tethadur and
BioSilicon; initiation and completion of clinical trials and obtaining
regulatory approval of product candidates; adverse side effects; ability to
attain profitability; ability to obtain additional capital; further impairment
of intangible assets; fluctuations in operating results; decline in royalty
revenues; ability to, and to find partners to, develop and market products;
termination of license agreements; competition and other developments
affecting sales of products; market acceptance; protection of intellectual
property and avoiding intellectual property infringement; retention of key
personnel; product liability; consolidation in the pharmaceutical and
biotechnology industries; compliance with environmental laws; manufacturing
risks; risks and costs of international business operations; credit and
financial market conditions; legislative or regulatory changes; volatility of
stock price; possible dilution; possible influence by Pfizer; absence of
dividends; and other factors described in our filings with the SEC. Given
these uncertainties, readers are cautioned not to place undue reliance on such
forward-looking statements. Our forward-looking statements speak only as of
the dates on which they are made. We do not undertake any obligation to
publicly update or revise our forward-looking statements even if experience or
future changes makes it clear that any projected results expressed or implied
in such statements will not be realized.

Follow pSivida on social media:

Twitter: https://twitter.com/pSividaCorp

Facebook: https://www.facebook.com/pages/PSivida-Corp/544893792199562

LinkedIn: http://www.linkedin.com/company/psivida

Google+:
https://plus.google.com/u/0/b/113754643626984244726/113754643626984244726/posts

The President's Blog: http://www.thechairmansblog.com/paul-ashton

Contact:

IN US:
Martin E. Janis & Company, Inc.
Beverly Jedynak, President
312-943-1123; 773-350-5793 (cell)
bjedynak@janispr.com
or
IN AUSTRALIA:
pSivida Corp.
Brian Leedman, Vice President, Investor Relations
+61 (0) 41 228 1780
brianl@psivida.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement